Sort by
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Prostate Cancer
78%
Neoplasm
52%
Bladder
42%
Malignant Neoplasm
33%
Diffusion MRI
32%
Immunohistochemistry
27%
Programmed Death 1 Ligand 1
23%
Bladder Cancer
23%
Biopsy Technique
23%
Acute Kidney Injury
23%
Living Donor
21%
Recurrent Disease
20%
Diagnostic Performance
20%
Cancer
20%
Upper Urinary Tract
19%
Kidney Transplantation
19%
Immunoglobulin A Nephropathy
19%
Reperfusion Injury
19%
Micropapillary
19%
Clear Cell Renal Cell Carcinoma
19%
Metastatic Carcinoma
18%
Immune Checkpoint Inhibitor
18%
Biological Marker
18%
Progression Free Survival
17%
Urinary System
16%
Magnetic Resonance Imaging
16%
Pheochromocytoma
15%
Computer Assisted Tomography
15%
Kidney Ischemia
14%
Messenger RNA
14%
Cisplatin
14%
Paraganglioma
12%
Stomach Carcinoma
12%
Ureter Cancer
12%
Liver Transplantation
12%
PARP Inhibitor
12%
Nail
12%
Seminal Vesicle
12%
Base Excision Repair
12%
Radical Nephrectomy
12%
Xenograft
12%
Cytokine
12%
Immunotherapy
11%
Chemokine
11%
Kidney Function
11%
Prognostic Factor
11%
Immunosuppressive Treatment
11%
Glomerular Filtration Rate
11%
Prostatectomy
10%
Pharmacology, Toxicology and Pharmaceutical Science
Transitional Cell Carcinoma
49%
Neoplasm
24%
Chemotherapy
22%
Malignant Neoplasm
20%
Cisplatin
19%
Acute Kidney Failure
19%
Renal Cell Carcinoma
19%
Programmed Death 1 Ligand 1
18%
Immune Checkpoint Inhibitor
18%
Progression Free Survival
16%
Recurrent Disease
15%
Gemcitabine
14%
Retrospective Study
13%
Prostate Cancer
13%
Chemoradiation Therapy
13%
Immunoglobulin A Nephropathy
12%
Hyperplasia
12%
Kidney Ischemia
12%
Uvomorulin
12%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
12%
Reperfusion Injury
12%
Messenger RNA
12%
Overall Survival
12%
Protein Tyrosine Kinase Inhibitor
10%
Steatosis
9%
Nivolumab
8%
Protein Tyrosine Kinase
8%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
8%
Immunotherapy
7%
Bladder Cancer
7%
Phase II Trials
7%
Prospective Study
7%
Diseases
6%
Paclitaxel
6%
Non Small Cell Lung Cancer
6%
Peroxisome Proliferator Activated Receptor Gamma
6%
Squamous Cell Carcinoma
6%
Effusion
6%
Angiomyolipoma
6%
Stenosis
6%
Hemodialysis
6%
Haplorhini
6%
Bruceantin
6%
Atezolizumab
6%
Kidney Metastasis
6%
Aminotransferase
6%
Tipifarnib
6%
Liver Cell Carcinoma
6%
Inflammatory Bowel Disease
6%
Carcinoma
6%
Immunology and Microbiology
Reperfusion
25%
Allograft
19%
Regulatory T Cell
15%
Islet Transplantation
14%
T Cell
13%
Monoclonal Antibody
12%
CD154
12%
Bone Marrow Transplantation
12%
B Cell
8%
Immunomodulation
8%
Immunosuppression
7%
Acute Graft Rejection
7%
Kidney Transplantation
6%
Liver Transplantation
6%
Reverse Transcriptase
6%
Bone Marrow Derived Mesenchymal Stem Cell
6%
Alanine
6%
Immune Tolerance
6%
Xenograft
6%
Gusperimus
6%
CD40 Ligand
6%
Epithelial Mesenchymal Transition
6%
Mesenchymal Stem Cell
6%
Long Term Survival
6%
Umbilical Cord Blood
6%
Haplorhini
6%
Next Generation Sequencing
6%
Gout
6%
Urinary Tract
6%
Squamous Cell
6%
Lamina Propria
6%
Magnetic Resonance Imaging
6%
Endothelial Cell Antibody
6%
Programmed Death-Ligand 1
6%
Neck
6%
Cell Differentiation
6%
C57BL 6 Mouse
5%
Cytokine
5%
CD4
5%
